How to appeal an Aetna radiation oncology — proton, sbrt, brachytherapy, imrt, iort denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for radiation oncology — proton, sbrt, brachytherapy, imrt, iort

Cited policy: Aetna Clinical Policy Bulletin (Proton/Neutron) and Aetna Medical Necessity Review on Stereotactic Body Radiation Therapy (SBRT)

SBRT covered for prostate when NCCN-aligned dose / fractionation (e.g., 36.25 Gy / 5 fx) is used in low-risk and favorable-intermediate-risk disease; intermediate / high-risk requires guideline support and risk-group documentation.

How Aetna denies radiation oncology — proton, sbrt, brachytherapy, imrt, iort — and how to counter it

Where Aetna pushes back: 1) SBRT prostate alleged 'experimental'; 2) Risk group not documented; 3) Dose / fractionation outside on-policy range.

Counter-arguments that hold up: Cite PACE-B (Tree Lancet Oncol 2022) — SBRT 36.25 Gy / 5 fx non-inferior to conventional / moderately hypofractionated RT in low and favorable-intermediate prostate at 5 yr. Cite HYPO-RT-PC (Widmark Lancet 2019) — ultra-hypofractionated 42.7 Gy / 7 fx non-inferior to 78 Gy / 39 fx in intermediate / high-risk at 5 yr. Cite ASTRO/ASCO/AUA Hypofractionated Prostate RT Guideline (Morgan JCO 2018, 2024 update). Document NCCN risk group + PSA + Gleason + clinical T-stage + Decipher when available.

What Aetna typically denies for radiation oncology — proton, sbrt, brachytherapy, imrt, iort

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For radiation oncology — proton, sbrt, brachytherapy, imrt, iort, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the radiation oncology — proton, sbrt, brachytherapy, imrt, iort treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Proton beam therapy
• SBRT prostate
• SBRT lung/liver/spine
• SRS brain
• LDR brachytherapy
• HDR brachytherapy

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.